Diagnosis and treatment of multiple sclerosis: a review

MP McGinley, CH Goldschmidt, AD Rae-Grant - Jama, 2021 - jamanetwork.com
Importance Multiple sclerosis (MS) is an autoimmune-mediated neurodegenerative disease
of the central nervous system characterized by inflammatory demyelination with axonal …

Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis

RHB Benedict, J DeLuca, G Phillips… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Cognitive and motor performance measures are commonly employed in multiple sclerosis
(MS) research, particularly when the purpose is to determine the efficacy of treatment. The …

Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course

X Zhou, R Baumann, X Gao, M Mendoza, S Singh… - Cell, 2022 - cell.com
Changes in gut microbiota have been associated with several diseases. Here, the
International Multiple Sclerosis Microbiome Study (iMSMS) studied the gut microbiome of …

Cognitive impairment in multiple sclerosis

ND Chiaravalloti, J DeLuca - The Lancet Neurology, 2008 - thelancet.com
Multiple sclerosis (MS) is a progressive disease of the CNS that is characterised by
widespread lesions in the brain and spinal cord. MS results in motor, cognitive, and …

[HTML][HTML] Intermittent fasting confers protection in CNS autoimmunity by altering the gut microbiota

F Cignarella, C Cantoni, L Ghezzi, A Salter, Y Dorsett… - Cell metabolism, 2018 - cell.com
Multiple sclerosis (MS) is more common in western countries with diet being a potential
contributing factor. Here we show that intermittent fasting (IF) ameliorated clinical course and …

Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in …

S Meyer-Moock, YS Feng, M Maeurer, FW Dippel… - BMC neurology, 2014 - Springer
Background There are a number of instruments that describe severity and progression of
multiple sclerosis and they are increasingly used as endpoints to assess the effectiveness of …

Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis

YC Learmonth, RW Motl, BM Sandroff, JH Pula… - BMC neurology, 2013 - Springer
Abstract Background The Patient Determined Disease Steps (PDDS) is a promising patient-
reported outcome (PRO) of disability in multiple sclerosis (MS). To date, there is limited …

Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting …

RK Burt, R Balabanov, J Burman, B Sharrack… - Jama, 2019 - jamanetwork.com
Importance Hematopoietic stem cell transplantation (HSCT) represents a potentially useful
approach to slow or prevent progressive disability in relapsing-remitting multiple sclerosis …

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

LK Fisniku, PA Brex, DR Altmann, KA Miszkiel… - Brain, 2008 - academic.oup.com
Clinically isolated syndromes (CIS), such as optic neuritis, brainstem or spinal cord
syndromes are frequently the first clinical presentations of multiple sclerosis. However, not …

Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis

RW Motl, JA Cohen, R Benedict… - Multiple Sclerosis …, 2017 - journals.sagepub.com
The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) includes
representatives from advocacy organizations, Food and Drug Administration (FDA) …